SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally advanced pancreatic cancer (LAPC).
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
SAN FRANCISCO and TOKYO, Sept. 20, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, ?FibroGen?) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., ?Astellas?) today announced that Jap… […]
SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside… […]
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). […]